Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
16,112 stopped studies · 89% state a reason
Over the 16,112 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04615845 | A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC | Phase 1 | terminated | Nov 4, 2020 | Pharmicell Co., Ltd. | Difficulties in patient recruitment. | Enrollment / accrual |
| NCT04827810 | A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to… | Phase 1 | suspended | Apr 1, 2021 | Fox Chase Cancer Center | Pending amendment to open further Cohorts | Other (stated, no rule matched) |
| NCT05117242 | Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With… | Phase 2 | terminated | Nov 11, 2021 | Genmab | Genmab has decided to discontinue further clinical development of acasunlimab following strategic… | Safety / toxicity |
| NCT05904080 | Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug… | Phase 2 | suspended | Jun 15, 2023 | National Cancer Institute (NCI) | Scheduled Interim Monitoring | Other (stated, no rule matched) |
| NCT01720186 | Evaluation of a Pneumotachograph (SPI) for the Production of PET and CT Acquisitions…(SPI COHERENCE) | N/A | terminated | Nov 2, 2012 | Institut Claudius Regaud | not stated | Not stated |
| NCT03362073 | Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients(CIVIK) | Phase 2 | terminated | Dec 5, 2017 | Pusan National University Yangsan Hospital | The study was terminated early due to the principal investigator's transition to another… | Investigator |
| NCT04021368 | RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome | Phase 1 | terminated | Jul 16, 2019 | Ryvu Therapeutics SA | RPD2 has been identified | Other (stated, no rule matched) |
| NCT04047693 | Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma | Phase 2 | terminated | Aug 7, 2019 | Pusan National University Yangsan Hospital | Poor accrual due to increased use of alternative neoadjuvant treatment options. | Enrollment / accrual |
| NCT04198480 | A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory… | Phase 1 / Phase 2 | terminated | Dec 13, 2019 | Shanghai JMT-Bio Inc. | Due to a change in the company's research strategy | Sponsor / business decision |
| NCT04614051 | A Phase 1 Study of Cellgram-DC in Patients With Advanced or Recurrent Epithelial Ovarian… | Phase 1 | terminated | Nov 3, 2020 | Pharmicell Co., Ltd. | Difficulties in patient recruitment. | Enrollment / accrual |
| NCT04638751 | ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | — | suspended | Nov 20, 2020 | Persephone Biosciences | Currently no funding to continue study. | Funding |
| NCT05052255 | RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Sep 22, 2021 | Ryvu Therapeutics SA | Sponsor decision | Sponsor / business decision |
| NCT06039202 | CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects… | Phase 2 | suspended | Sep 15, 2023 | Holy Stone Healthcare Co., Ltd | Strategy under discussion | Sponsor / business decision |
| NCT06213051 | Comparison of Self-collection Using Dry Compared to Wet Swabs for HPV Detection(HPV) | — | suspended | Jan 19, 2024 | Foundation for Innovative New Diagnostics, Switzerland | funding issues | Funding |
| NCT06560385 | Alleviation of Alopecia in Breast Cancer Patient Using Synbiotics Formula | N/A | terminated | Aug 19, 2024 | GenieBiome Limited | No enough subjects within the recruitment period | Enrollment / accrual |
| NCT06616623 | Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell… | Phase 1 | suspended | Sep 27, 2024 | Dwight Owen | Pending ICF update | Other (stated, no rule matched) |
| NCT07061080 | Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab(RAGNAR) | Phase 2 | terminated | Jul 11, 2025 | Grupo Espanol de Tumores Neuroendocrinos | AMGEN, due to a change in priorities within the Tarlatamab programme, has decided to withdraw its… | Other (stated, no rule matched) |
| NCT00421096 | Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine…(GEMCOL) | Phase 2 | terminated | Jan 11, 2007 | Centre Oscar Lambret | Problems of recruitment | Enrollment / accrual |
| NCT01613482 | TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention(TSARINE) | Phase 3 | terminated | Jun 7, 2012 | Centre Oscar Lambret | Lack of enrollment | Enrollment / accrual |
| NCT03585465 | Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory /…(Metro-PD1) | Phase 1 / Phase 2 | terminated | Jul 13, 2018 | Centre Oscar Lambret | Analysis conducted on spring 2025, according to the provisional schedule: the results were… | Other (stated, no rule matched) |
| NCT04040673 | RAman For Thyroid cancER(RAFTER) | — | withdrawn | Aug 1, 2019 | Gloucestershire Hospitals NHS Foundation Trust | Covid19 halted study | COVID-19 / pandemic |
| NCT04738487 | Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475)… | Phase 3 | terminated | Feb 4, 2021 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT05041335 | Wet Heparinized Suction for Abdominal Cancer(EUS Heparin) | N/A | withdrawn | Sep 13, 2021 | H. Lee Moffitt Cancer Center and Research Institute | study no longer proceeding | Other (stated, no rule matched) |
| NCT05264974 | Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization | Phase 1 | suspended | Mar 3, 2022 | University of Florida | seeking additional funding | Funding |
| NCT05937074 | Metabolic Response to Food in Lung Cancer(METRIC) | — | terminated | Jul 10, 2023 | Pennington Biomedical Research Center | Poor accrual. | Enrollment / accrual |
| NCT01947140 | Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies(PDX+Romi) | Phase 1 / Phase 2 | terminated | Sep 20, 2013 | Jennifer Amengual | Lack of funding and recruitment complications caused by COVID-19 | COVID-19 / pandemic |
| NCT02926729 | Real-Time Assessment Of Breast Cancer Surgical Specimen Margins With Nonlinear Microscopy | N/A | terminated | Oct 6, 2016 | Beth Israel Deaconess Medical Center | Low enrollment | Enrollment / accrual |
| NCT04808427 | Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate… | N/A | suspended | Mar 22, 2021 | National Cancer Institute (NCI) | On hold pending consideration of an amendment to increase recruitment. | Enrollment / accrual |
| NCT05316688 | A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell… | Phase 1 / Phase 2 | terminated | Apr 7, 2022 | University of Washington | Terminated due to suboptimal delineation of fluorescence between tumor and native oral cavity… | Other (stated, no rule matched) |
| NCT05764395 | Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma… | Phase 2 | terminated | Mar 10, 2023 | Vanderbilt-Ingram Cancer Center | Drug unavailable | Other (stated, no rule matched) |
| NCT06268574 | Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML(RIVER-52) | Phase 2 | terminated | Feb 20, 2024 | Ryvu Therapeutics SA | Sponsor decision | Sponsor / business decision |
| NCT06397313 | RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis(POTAMI-61) | Phase 2 | terminated | May 2, 2024 | Ryvu Therapeutics SA | Sponsor decision | Sponsor / business decision |
| NCT06858501 | Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk… | Phase 2 | withdrawn | Mar 5, 2025 | Children's Oncology Group | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT06870916 | Supporting Informed Decision Making About Multi-cancer Early Detection Testing | — | suspended | Mar 11, 2025 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT07297160 | CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors(CALySSEY) | Phase 1 | withdrawn | Dec 22, 2025 | Baylor College of Medicine | The study was revised into two separate protocols to separate treatments. We will submit as… | Other (stated, no rule matched) |
| NCT07814365 | PBI for Low-risk Breast Cancer | N/A | withdrawn | Sep 11, 2026 | Fudan University | funding issue | Funding |
| NCT03016156 | Determination of the Sensitivity and Specificity of a Smartphone Application to Detect… | N/A | terminated | Jan 10, 2017 | St. Jude Children's Research Hospital | Accrual was slow. | Enrollment / accrual |
| NCT03634267 | MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA… | Phase 1 | terminated | Aug 16, 2018 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT03804255 | Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision… | — | withdrawn | Jan 15, 2019 | ECOG-ACRIN Cancer Research Group | Study closed before patients enrolled | Enrollment / accrual |
| NCT04286386 | Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam | — | withdrawn | Feb 27, 2020 | M.D. Anderson Cancer Center | No Participants Enrolled | Enrollment / accrual |
| NCT05076266 | COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151)… | — | terminated | Oct 13, 2021 | Eastern Cooperative Oncology Group | slower than expected accrual. | Enrollment / accrual |
| NCT05080946 | Using Aspirin to Improve Immunological Features of Ovarian Tumors | Early Phase 1 | suspended | Oct 18, 2021 | H. Lee Moffitt Cancer Center and Research Institute | Study drug is expiring. Will reopen when new drug is received. | Other (stated, no rule matched) |
| NCT05378464 | Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab… | Phase 1 | suspended | May 18, 2022 | H. Lee Moffitt Cancer Center and Research Institute | Wait for the DLT period with our current patient and will not be enrolling any more. | Enrollment / accrual |
| NCT05908786 | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in… | Phase 1 / Phase 2 | terminated | Jun 18, 2023 | Hoffmann-La Roche | Study was closed early as the sponsor decided not to continue development of certain treatment… | Sponsor / business decision |
| NCT06129760 | Glioblastoma Remote Monitoring and Care - Research Protocol | N/A | suspended | Nov 13, 2023 | Case Comprehensive Cancer Center | PI decision | Other (stated, no rule matched) |
| NCT06274034 | MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors | Early Phase 1 | terminated | Feb 23, 2024 | Mayo Clinic | Funds expired | Funding |
| NCT06421155 | Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia | N/A | suspended | May 20, 2024 | Case Comprehensive Cancer Center | Voluntary hold by PI | Other (stated, no rule matched) |
| NCT06943664 | Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory,… | Phase 2 | withdrawn | Apr 24, 2025 | Roswell Park Cancer Institute | Lack of funding | Funding |
| NCT06968195 | Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or… | Phase 1 | suspended | May 13, 2025 | Roswell Park Cancer Institute | awaiting agreement with Sponsor | Other (stated, no rule matched) |
| NCT07039630 | A Food Security Intervention for the Prevention of Cancer in Low-income Families | N/A | suspended | Jun 26, 2025 | Roswell Park Cancer Institute | behavioral intervention is being prepared | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 4 days agoSource updated Sep 21, 2026source: clinicaltrials